Your browser doesn't support javascript.
loading
Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use.
Winstanley, Erin L; Thacker, Emily P; Choo, Lyn Yuen; Lander, Laura R; Berry, James H; Tofighi, Babak.
Affiliation
  • Winstanley EL; Department of Behavioral Medicine and Psychiatry, School of Medicine and Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, United States.
  • Thacker EP; Department of Neuroscience, West Virginia University, Morgantown, WV, United States.
  • Choo LY; Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, PA, United States.
  • Lander LR; West Virginia Clinical and Translational Science Institute, West Virginia University, Morgantown, WV, United States.
  • Berry JH; Department of Behavioral Medicine and Psychiatry, School of Medicine and Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, United States.
  • Tofighi B; Department of Neuroscience, West Virginia University, Morgantown, WV, United States.
Drug Alcohol Depend Rep ; 5: 100091, 2022 Dec.
Article in En | MEDLINE | ID: mdl-36844166
Background: While barriers to accessing buprenorphine (BUP) therapy have been well described, little is known about pharmacy-related barriers. The objective of this study was to estimate the prevalence of patient-reported problems filling BUP prescriptions and determine whether these problems were associated with illicit use of BUP. The secondary objectives included identifying motivations for illicit BUP use and the prevalence of naloxone acquisition among patients prescribed BUP. Methods: Between July 2019 and March 2020, 139 participants receiving treatment for an opioid use disorder (OUD) at two sites within a rurally-located health system, completed an anonymous 33-item survey. A multivariable model was used to assess the association between pharmacy-related problems filling BUP prescriptions and illicit substance use. Results: More than a third of participants reported having problems filling their BUP prescription (34.1%, n = 47) with the most commonly reported problems being insufficient pharmacy stock of BUP (37.8%, n = 17), pharmacist refusal to dispense BUP (37.8%, n = 17), and insurance problems (34.0%, n = 16). Of those who reported illicit BUP use (41.5%, n = 56), the most common motivations were to avoid/ease withdrawal symptoms (n = 39), prevent/reduce cravings (n = 39), maintain abstinence (n = 30), and treat pain (n = 19). In the multivariable model, participants who reported a pharmacy-related problems were significantly more likely to use illicitly obtained BUP (OR=8.93, 95% CI: 3.12, 25.52, p < 0.0001). Conclusion: Efforts to improve BUP access have primarily focused on increasing the number of clinicians waivered to prescribe; however, challenges persist with BUP dispensing and coordinated efforts may be needed to systematically reduce pharmacy-related barriers.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Risk_factors_studies Language: En Journal: Drug Alcohol Depend Rep Year: 2022 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Risk_factors_studies Language: En Journal: Drug Alcohol Depend Rep Year: 2022 Document type: Article Affiliation country: Country of publication: